Date: 2016-10-10
Type of information: Milestone
Compound: new targets among deubiquitinating enzymes - ubiquitin-specific proteases (USPs) and their inhibitors
Company: Hybrigenics (France) Servier (France)
Therapeutic area: Cancer - Oncology - CNS diseases - Psychiatric diseases - Rheumatic diseases - Ophthalmological diseases - Metabolic diseases - Cardiovascular diseases
Type agreement: research - R&D - licensing
Action mechanism:
Disease:
Details:
- • On October 10, 2011, Hybrigenics and Servier have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics will identify and validate new targets among DUBs in these therapeutic areas. Hybrigenics will also screen potential therapeutic agents able to modulate four undisclosed targets, already chosen as exclusive DUBs of interest under the collaboration. Servier will provide the compounds to be screened, develop the selected compounds and commercialize the approved drugs. Hybrigenics activities under this collaboration may also lead to the discovery of companion diagnostics, potentially needed for such therapeutic drugs.
Financial terms: Financial details were not disclosed.
Latest news:
- • On October 10, 2016, Hybrigenics announced a new step in its R&D partnership with Servier in the field of Ubiquitin-Specific Proteases (USPs). The research collaboration started in 2011 and has focused on one USP especially relevant to oncology. It has now reached its objectives, triggering a €1.5 million milestone payment to Hybrigenics. Servier will take charge of the continuation of this R&D program in oncology. Hybrigenics remains associated to its success, with a total of up to €12 million further payments linked to potential additional milestones until drug registration.
Hybrigenics will intensify its own research to validate other USPs as innovative therapeutic targets and to discover new chemical series to efficiently inhibit them.
- • On January 26, 2015, Hybrigenics announced the extension of its partnership with Servier to discover new drugs which inhibit Ubiquitin-Specific Proteases (USPs). This partnership was initiated in October 2011 and a first research milestone has been reached one year ago in the field of oncology. The overall work and achievement have already given rise to total cumulated revenues of close to € 4.3 million for Hybrigenics. The results obtained reinforce our confidence in one USP as a target of interest against certain cancers and justify the research extension for one year, with an additional amount of € 0.92 million committed to Hybrigenics.
• On January 20, 2014, Hybrigenics has announced the achievement of a first drug discovery milestone in connection with the ongoing research collaboration with Servier on ubiquitin-specific proteases (USPs) and their inhibitors. Hybrigenics has received € 0.33 million in recognition of this achievement.
Is general: Yes
